Warnex Inks Pharmacogenetics Services Deal with Schering-Plough Canada | GenomeWeb
NEW YORK (GenomeWeb News) - Warnex Medical Laboratories will develop several new pharmacogenetic assays for Schering-Plough Canada, Warnex said last week.
 
Under the agreement, Warnex said it will supply pharmacogenetic and molecular biology services for Schering-Plough’s clinical trials for cancer and infectious disease therapeutics.
 
Warnex said the company is using its services to identify patients who are more likely to respond to a treatment or who are less likely to have an adverse event.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.